KIT exon 17 mutants Inhibitors
1 drugsAbout KIT exon 17 mutants
KIT exon 17 mutants are receptor tyrosine kinases that drive uncontrolled cell proliferation by constitutively activating the KIT protein. These mutations affect cell signaling pathways regulating cell growth, differentiation, and survival.
KIT exon 17 mutants are compelling therapeutic targets due to their functional impact on cell proliferation. Currently, there is no genetic evidence directly linking these specific mutations to broader disease risks.
AYVAKIT is the only FDA-approved drug targeting KIT exon 17 mutants, with 6 indications. It is a small molecule drug developed by BLUEPRINT MEDICINES.
Top KIT exon 17 mutants Drugs
BLUEPRINT MEDICINES is the only company with an approved drug targeting KIT exon 17 mutants.
The market is highly concentrated, suggesting high barriers to entry or untapped potential.
KIT exon 17 mutants Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KIT exon 17 mutants, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
KIT exon 17 mutants Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on KIT exon 17 mutants. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 | 100% |
| Phase 2 | 8 | 1 | 0 | 7 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KIT exon 17 mutants Drug Approval Timeline (2020 - 2020)
The first and only drug, AYVAKIT, was approved in 2020.
Recent approval suggests a growing interest, but market saturation may occur quickly.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on KIT exon 17 mutants. A trial counts if an approved drug acting on KIT exon 17 mutants is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.